Jasper Therapeutics, based in Palo Alto, Calif., focuses on therapies to enable safer hematopoietic cell transplants. Its lead clinical asset, JSP191, is a humanized monoclonal antibody that targets CD117 and is being developed as a single-agent conditioning regimen to replace toxic chemotherapy and radiation. JSP191 is currently in a Phase 1/2 dose‑escalation and expansion trial for patients with severe combined immunodeficiency (SCID) who had prior poor transplant outcomes and has been evaluated in more than 80 healthy volunteers and patients. Jasper plans to expand the Phase 1/2 study to include patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and to conduct IND‑enabling studies for other rare monogenic and autoimmune diseases. Development of JSP191 is supported by a collaboration with the California Institute for Regenerative Medicine (CIRM). Financially, the company has raised more than $50 million to date following a $14.1 million expansion of its Series A. Jasper Therapeutics is focused on developing safer conditioning and therapeutic agents to expand the use of curative hematopoietic stem cell transplants and gene therapies. Its lead product candidate, JSP191 (formerly AMG191), is a humanized anti-CD117 monoclonal antibody in clinical development as a conditioning agent to clear hematopoietic stem cells from bone marrow. JSP191 is currently being evaluated in an ongoing Phase 1 dose‑escalation trial for patients with severe combined immunodeficiency (SCID), with plans to expand clinical development into patients receiving transplants for AML, MDS and for stem cell‑directed gene therapies. The company launched with a $35 million Series A financing, and the proceeds will be used to advance clinical development of JSP191. Development of JSP191 is supported by a collaboration with the California Institute for Regenerative Medicine, which has committed a total of $23 million in grant support. Amgen licensed worldwide rights to JSP191 to Jasper and contributed translational science and materials from Stanford University.

Total raised

$49M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2020